A study examining the effect of the brolcizumab on neovascular age-related macular degeneration in Japanese with treat and extend

A prospective study examining the effect of brolcizumab on neovascular age-related macular degeneration in Japanese with treat and extend - A prospective stud ; brolcizumab on nAMD in Japanese with treat and extend

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044374

Enrollment

Registered

2021-05-31

Start date

2020-11-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: choroidal neovascularization due to exudative age-related macular degeneration is confirmed by FA/IA within 3000 micro meter centered on the fovea centralis. Visual acuity is reduced due to exudative changes in the macula. Within 6 months of onset There is consent for this research Untreated

Exclusion criteria

Exclusion criteria: Eye surgery within 3 months There are other disorders that cause vision loss History of vitreous surgery History of grid-like photocoagulation History of cerebrocardiovascular events within 6 months Adults who are judged to lack informed consent Doctor judges that it is not suitable for this study

Design outcomes

Primary

Measure	Time frame
Percentage of patients with visual acuity and dosing interval extended to 12 weeks after 12 or 24 months	—

Countries

Japan

Contacts

Public ContactSatoru Inoda

Jichi Medical University Ophthalmology

r1208is@jichi.ac.jp0285587382

Outcome results